Masmoudi D, Villalba M, Alix-Panabieres C. Natural killer cells: the immune frontline against circulating tumor cells. J Exp Clin Cancer Res. 2025;44:118.
Google Scholar
Zhao L, Li R, Meng X-Y, Guo Y-X, Liu L, Li S-Y, et al. Acquisition of vimentin by trogocytosis inhibits the NK cell-mediated immune response against CTCs. Cell Mol Immunol. 2026;23:823–39.
Kim J, Park S, Kim J, Kim Y, Yoon HM, Rayhan BR, et al. Trogocytosis-mediated immune evasion in the tumor microenvironment. Exp Mol Med. 2025;57:1–12.
Google Scholar
Ramezani F, Panahi Meymandi AR, Akbari B, Tamtaji OR, Mirzaei H, Brown CE, et al. Outsmarting trogocytosis to boost CAR NK/T-cell therapy. Mol Cancer. 2023;22:183.
Google Scholar
Glassy MC. Cell surface vimentin: a natural human immune response target for immunotherapy. Front Mol Med. 2025;5:1552323.
Google Scholar
Peng JM, Chiu CF, Cheng JH, Liu HY, Chang YL, Luo JW, et al. Evasion of NK cell immune surveillance via the vimentin-mediated cytoskeleton remodeling. Front Immunol. 2022;13:883178.
Google Scholar
Shin MH, Oh E, Minn D. Current developments in NK cell engagers for cancer immunotherapy: focus on CD16A and NKp46. Immune Netw. 2024;24:e34.
Google Scholar
Carrillo J, Gill JM, Redfern C, Babic I, Nomura N, Shah DK, et al. A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases. Neurooncol Adv. 2024;6:vdae166.
Google Scholar
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022;28:2133–44.
Google Scholar
Satelli A, Li SL. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033–46.
Google Scholar
